mobocertinib
takeda
['sclc', 'mobocertinib', 'nsclc']
going to the #aacr23 session on advances in #nsclc? lots of activity in the #egfr #exon20 space, e.g. this phase 1/2 trial in : activity and safety of mobocertinib (tak-788) in previously treated nsclc with egfr exon20 insertion mutations 
Executive Editor of Cancer Discovery @CD_AACR, published by @AACR. @BBS_Harvard/@DanaFarber alum. Native New Yorker. Views/likes/RTs are my own. She/her